



**Cancer Endorsement Maintenance
Steering Committee Meeting
May 23-24, 2012**

National Quality Forum
Executive Building
1030 15th Street, NW, Suite 900
Washington, DC 20005
(202) 783-1300

Please use the following information to access the conference call line:

Dial-in Number: (855) 226-0347

Event Confirmation Code: 78411449 *please note the confirmation code is different for Day 2

Event Title: Cancer Endorsement Maintenance Steering Committee Meeting

AGENDA

Day 1: May 23

- 8:30am **Continental Breakfast**
- 9:00am **Welcome**
Angela Franklin, JD, Senior Director
Stephen Lutz, MD (Chair)
- 9:10am **Introductions and Disclosure of Interest**
Ann Hammersmith, JD
- 9:20am **Overview of Evaluation Process**
Ms. Franklin
Lindsey Tighe, MS, Project Manager
- 9:30am **Consideration of Candidate Measures (Breast)**
- 0219: Post breast conservation surgery irradiation (ACS)
 - 0220: Adjuvant hormonal therapy (ACS)
 - 0221: Needle biopsy to establish diagnosis of cancer precedes surgical excision/resection (ACS)
 - 0559: Combination chemotherapy is considered or administered within 4 months (120 days) of diagnosis for women under 70 with AJCC T1c, or Stage II or III hormone receptor negative breast cancer (ACS)



- 11:30am **Break**
- 11:45am **Consideration of Candidate Measures (Breast continued)**
- 1857: Trastuzumab not administered to breast cancer patients when human epidermal growth factor receptor 2 (HER2) is negative or undocumented (ASCO)
 - 1858: Trastuzumab administered to patients with AJCC stage I (T1c) – III, human epidermal growth factor receptor 2 (HER2) positive breast cancer (ASCO)
- 12:30pm **NQF Member and Public Comment**
- 12:45pm **Lunch**
- 1:15pm **Consideration of Candidate Measures (Breast continued)**
- 1878: Human epidermal growth factor receptor 2 (HER2) testing in breast cancer (ASCO)
 - 1855: Quantitative HER2 evaluation by IHC uses the system recommended by the ASCO/CAP guidelines (CAP)
 - 0623: History of Breast Cancer – Cancer Surveillance (ActiveHealth Management)
 - 0031: Breast Cancer Screening (NCQA)
- 3:30pm **Break**
- 3:45pm **Consideration of Candidate Measures (Breast, Colorectal)**
- 0387: Oncology: Hormonal Therapy for Stage IC Through IIIC, ER/PR Positive Breast Cancer (AMA-PCPI)
 - 0391: Breast Cancer Resection Pathology Reporting- pT category (primary tumor) and pN category (regional lymph nodes) with histologic grade (AMA-PCPI; CAP)
 - 0392: Colorectal Cancer Resection Pathology Reporting- pT category (primary tumor) and pN category (regional lymph nodes) with histologic grade (AMA-PCPI; CAP)
- 4:45pm **NQF Member and Public Comment**
- 5:00 pm **Adjourn**



**Cancer Endorsement Maintenance
Steering Committee Meeting
May 23-24, 2012**

Please use the following information to access the conference call line:

Dial-in Number: (855) 226-0347

Event Confirmation Code: 78413277 *please note the confirmation code is different from Day 1

Event Title: Cancer Endorsement Maintenance Steering Committee Meeting

Day 2: May 24

8:30am **Continental Breakfast**

9:00am **Welcome, Recap of Day 1**

Dr. Lutz

Ms. Franklin

9:15am **Consideration of Candidate Measures (Colorectal)**

- 0223: Adjuvant chemotherapy is considered or administered within 4 months (120 days) of surgery to patients under the age of 80 with AJCC III (lymph node positive) colon cancer (ACS)
- 0225: At least 12 regional lymph nodes are removed and pathologically examined for resected colon cancer (ACS)
- 0385: Oncology: Chemotherapy for Stage IIIA through IIIC Colon Cancer Patients (AMA-PCPI)

10:30am **Break**

10:45am **Consideration of Candidate Measures (Colorectal continued)**

- 1859: KRAS gene mutation testing performed for patients with metastatic colorectal cancer who receive anti-epidermal growth factor receptor monoclonal antibody therapy (ASCO)
- 1860: Anti-epidermal growth factor receptor monoclonal antibody therapy not received by metastatic colorectal cancer patients with KRAS gene mutation (ASCO)

11:45am **Measure Gaps**

12:15pm **NQF Member and Public Comment**

12:30pm **Next Steps**

Ms. Franklin



NATIONAL
QUALITY FORUM

1030 15TH STREET, NW, SUITE 800
WASHINGTON, DC 20005
202 783-1300 MAIN 783-3434 FAX

Ms. Tighe

12:45pm

Adjourn

Box lunches will be provided for Steering Committee members